Mechanism of action
Methylene blue acts as a cofactor for NADPH-methemoglobin reductase, an enzyme that reduces methemoglobin (Fe³⁺) back to functional hemoglobin (Fe²⁺). At low doses, methylene blue accelerates the conversion of methemoglobin to hemoglobin by serving as an electron acceptor and donor in the hexose monophosphate shunt pathway.
At high doses, methylene blue paradoxically acts as an oxidizing agent and can actually increase methemoglobin levels, producing the opposite of the intended therapeutic effect. This dose-dependent biphasic action is a classic exam concept.
In ifosfamide-induced encephalopathy, methylene blue inhibits the formation of neurotoxic metabolites, particularly chloroacetaldehyde, though the precise mechanism remains incompletely understood. Methylene blue also has weak monoamine oxidase inhibitor (MAOI) properties, which accounts for its potential to precipitate serotonin syndrome when combined with serotonergic agents.
- Methylene blue is contraindicated in G6PD deficiency due to risk of severe hemolytic anemia
- Methylene blue has weak MAOI activity and can precipitate serotonin syndrome with SSRIs, SNRIs, or other serotonergic drugs
- Chocolate-brown blood and cyanosis unresponsive to oxygen suggest methemoglobinemia
- Methylene blue causes falsely low pulse oximetry readings (typically ~85%) and blue-green urine discoloration
- Used as antidote for ifosfamide-induced encephalopathy by inhibiting neurotoxic metabolite formation
- Requires functioning G6PD and NADPH-methemoglobin reductase; ineffective in congenital methemoglobinemia
- Response to methylene blue in methemoglobinemia is rapid (30–60 minutes) and diagnostic of acquired causes
- At high doses methylene blue paradoxically acts as an oxidizing agent and can worsen methemoglobinemia
Indications
The primary indication for methylene blue is acquired methemoglobinemia, particularly drug-induced or chemical-induced cases. Common causative agents include:
- Dapsone
- Local anesthetics (benzocaine, prilocaine, lidocaine)
- Nitrites and nitrates
- Phenazopyridine
- Sulfonamides
- Aniline dyes
Methylene blue is indicated when methemoglobin levels exceed 20% or when patients are symptomatic at lower levels (cyanosis, dyspnea, altered mental status). It is not used for congenital methemoglobinemia due to NADH-cytochrome b5 reductase deficiency, as the enzyme pathway it depends on is absent.
Ifosfamide-induced encephalopathy is another important indication. Methylene blue can be used prophylactically or therapeutically to prevent or reverse neurotoxicity manifesting as confusion, hallucinations, seizures, or coma.
Other uses include:
- Diagnostic dye in surgery (sentinel lymph node mapping, fistula identification)
- Vasoplegic syndrome refractory to vasopressors
- Indicator dye in various diagnostic procedures
Pharmacokinetics
Methylene blue is administered intravenously for acute methemoglobinemia. After IV administration, it is rapidly distributed to tissues and crosses the blood-brain barrier.
Onset of action is rapid, typically within 30 minutes, with visible reduction in cyanosis as methemoglobin levels decrease. Peak effect occurs at approximately 1 hour.
Metabolism occurs via tissue reduction to leucomethylene blue, the active form responsible for methemoglobin reduction. Methylene blue undergoes hepatic metabolism and is excreted in urine and bile. Renal excretion of unchanged drug and metabolites produces characteristic blue-green discoloration of urine, which should be anticipated and explained to patients.
Half-life is approximately 5–6.5 hours. The drug's blue color can interfere with pulse oximetry readings, often producing falsely low SpO₂ values around 85%, which is a commonly tested clinical pearl.
Adverse effects
The most serious adverse effect is hemolytic anemia in patients with G6PD deficiency. Because methylene blue depends on NADPH generated via the hexose monophosphate shunt (requiring G6PD), patients with G6PD deficiency cannot regenerate the reduced form of methylene blue, leading to oxidative stress and hemolysis. This is an absolute contraindication.
Common adverse effects include:
- Blue-green discoloration of urine (universal, harmless, but should be warned about)
- Nausea, vomiting, abdominal pain
- Dizziness, headache, confusion
- Diaphoresis
- Localized pain at injection site
- Skin discoloration (bluish tint)
Serotonin syndrome is a potentially life-threatening interaction when methylene blue is administered to patients taking serotonergic medications (SSRIs, SNRIs, MAOIs, tramadol, linezolid). The weak MAOI activity of methylene blue can precipitate this syndrome, manifesting as altered mental status, autonomic instability, hyperthermia, and neuromuscular abnormalities.
Paradoxical methemoglobinemia can occur with excessive doses, as methylene blue itself becomes an oxidizing agent at high concentrations.
Other reported effects include hypertension, chest pain, dyspnea, and rarely anaphylactoid reactions.
Contraindications and warnings
Absolute contraindications:
- G6PD deficiency — risk of severe hemolytic anemia
- Severe renal impairment (methylene blue accumulation can worsen outcomes)
Relative contraindications and warnings:
- Concurrent use of serotonergic agents — risk of serotonin syndrome. A washout period is recommended before elective use, though in life-threatening methemoglobinemia this risk may be acceptable.
- Pregnancy — limited data; use only if benefits outweigh risks. Methylene blue crosses the placenta.
- Breastfeeding — excretion in breast milk unknown; caution advised.
- NADH-cytochrome b5 reductase deficiency (congenital methemoglobinemia) — methylene blue is ineffective because the enzymatic pathway is absent.
- Patients with anemia or cardiovascular disease require close monitoring as oxygen-carrying capacity may already be compromised.
Interference with diagnostic tests: Methylene blue causes falsely low pulse oximetry readings (typically around 85%) and can interfere with colorimetric laboratory assays. Clinical correlation is essential, as the SpO₂ does not reflect true arterial oxygen saturation in the presence of methylene blue.
Drug interactions
The most clinically significant interactions involve serotonergic drugs. Methylene blue has MAOI-like properties and can precipitate serotonin syndrome when combined with:
- Selective serotonin reuptake inhibitors (SSRIs)
- Serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Tricyclic antidepressants
- MAO inhibitors
- Tramadol
- Meperidine
- Linezolid
- St. John's wort
- Triptans
The FDA has issued warnings about this interaction. When methylene blue must be used urgently (e.g., for severe methemoglobinemia), the risk-benefit ratio may favor administration despite concurrent serotonergic therapy, but patients require close monitoring for signs of serotonin syndrome.
Drugs that cause methemoglobinemia may necessitate methylene blue use but are not interactions per se; these include dapsone, benzocaine, nitrates, and sulfonamides.
Methylene blue may interfere with laboratory tests using colorimetric or spectrophotometric methods due to its intense blue color.
Clinical pearls
- Always check G6PD status before administering methylene blue if time permits; if unavailable and methemoglobinemia is life-threatening, weigh the risks carefully.
- Blue-green urine is expected and harmless — warn patients to prevent alarm.
- Methylene blue causes falsely low pulse oximetry readings (typically ~85%); rely on arterial blood gas and co-oximetry instead.
- Chocolate-brown blood that does not turn red when exposed to air is pathognomonic for methemoglobinemia.
- Methylene blue response is rapid and diagnostic: improvement within 30–60 minutes confirms acquired (not congenital) methemoglobinemia.
- At high doses, methylene blue paradoxically acts as an oxidizing agent, worsening methemoglobinemia.
- Screen for serotonergic medications before administration to avoid serotonin syndrome; this interaction can be life-threatening.
- Methylene blue is ineffective in congenital methemoglobinemia due to absent NADH-cytochrome b5 reductase; ascorbic acid is an alternative.
- Used off-label for ifosfamide-induced encephalopathy with rapid reversal of neurotoxicity.
- Methylene blue has a role in refractory vasoplegic shock (sepsis, post-cardiac surgery) due to its vasoconstrictive properties.
G6PD = Gone, so (don't) Pick (methylene) Blue — contraindicated in G6PD deficiency
Practice questions
1. A 35-year-old man with a history of Pneumocystis jirovecii pneumonia prophylaxis presents to the ED with cyanosis and shortness of breath. His oxygen saturation by pulse oximetry is 85% on room air, but arterial blood gas shows PaO₂ of 95 mmHg. Co-oximetry reveals methemoglobin level of 28%. He takes dapsone daily. The physician prepares to administer methylene blue but first orders which of the following tests?
2. A 42-year-old woman undergoing chemotherapy with ifosfamide develops confusion, visual hallucinations, and disorientation 12 hours after her infusion. Neurological examination shows no focal deficits. CT head is unremarkable. Which medication is most appropriate to reverse her encephalopathy?
3. A 28-year-old man presents with severe methemoglobinemia (methemoglobin 32%) after benzocaine spray use during endoscopy. He receives methylene blue IV and improves dramatically within 45 minutes. He takes sertraline 100 mg daily for depression. Six hours later, he develops agitation, diaphoresis, tremor, hyperreflexia, and a temperature of 39.2°C (102.6°F). What is the most likely cause?
Frequently asked questions
How does methylene blue work?
Methylene blue reduces methemoglobin (Fe³⁺) back to functional hemoglobin (Fe²⁺) by acting as a cofactor for NADPH-methemoglobin reductase. At therapeutic doses, it accelerates electron transfer in the hexose monophosphate shunt pathway, rapidly restoring oxygen-carrying capacity. This mechanism requires functional G6PD enzyme to generate NADPH, which is why methylene blue is contraindicated in G6PD deficiency. At high doses, it paradoxically acts as an oxidizing agent.
What are the side effects of methylene blue?
The most serious side effect is hemolytic anemia in patients with G6PD deficiency, which can be life-threatening. Common side effects include blue-green discoloration of urine (universal but harmless), nausea, vomiting, dizziness, headache, and localized pain at the injection site. Methylene blue can also cause serotonin syndrome when combined with serotonergic drugs like SSRIs due to its weak MAOI properties. High doses can paradoxically worsen methemoglobinemia. Pulse oximetry readings become unreliable, typically showing falsely low values around 85%.
Is methylene blue a controlled substance?
No, methylene blue is not a controlled substance in the United States or most other countries. It is a prescription medication classified as a diagnostic and therapeutic agent with oxidation-reduction properties. It does not have abuse potential and is not scheduled under the Controlled Substances Act. However, it does require medical supervision for administration due to its narrow therapeutic window and potential for serious adverse effects, particularly in patients with G6PD deficiency or those taking serotonergic medications.
What is methylene blue used to treat?
Methylene blue is primarily used to treat acquired methemoglobinemia caused by drugs (dapsone, benzocaine, nitrates) or chemicals. It is indicated when methemoglobin levels exceed 20% or when patients are symptomatic with cyanosis, dyspnea, or altered mental status. It also treats ifosfamide-induced encephalopathy, preventing or reversing neurotoxicity. Additional uses include serving as a diagnostic dye during surgery for sentinel lymph node mapping and fistula identification, and rarely for refractory vasoplegic syndrome. It is not effective for congenital methemoglobinemia due to enzyme deficiency.
Methylene blue vs ascorbic acid for methemoglobinemia — what is the difference?
Methylene blue is the first-line treatment for acquired methemoglobinemia with rapid onset (30–60 minutes), working through NADPH-methemoglobin reductase. Ascorbic acid (vitamin C) reduces methemoglobin slowly over hours to days via a non-enzymatic pathway and is reserved for patients with contraindications to methylene blue, particularly G6PD deficiency. Ascorbic acid is much less effective and is typically used as adjunctive therapy or when methylene blue cannot be given. In acute, symptomatic methemoglobinemia, methylene blue is preferred due to its rapid action and efficacy.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: V03AB17WHO ATC/DDD index: V04CG05
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.